The global pulmonary arterial hypertension market size was valued at USD 6.9 billion in 2020, and is predicted to be worth around USD 10.9 billion by 2030, registering a CAGR of 5.1% during the forecast period 2022 to 2030.
Growing initiatives by key market players, high prevalence of pulmonary arterial hypertension, adoption rate, availability of reimbursement, and entry of generics are some of the key drivers of this market. As per the American Lung Association, about 500 to 1000 new PAH patients are being diagnosed every year in the U.S.
The key factors driving the market growth include the increasing prevalence of pulmonary arterial hypertension, drug development and technological advancements, product approvals, and initiatives by key companies.
The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.
|Market Size||US$ 10.9 billion by 2030|
|Growth Rate||CAGR of 5.1% From 2022 to 2030|
|Largest Market||North America|
|Forecast Period||2022 to 2030|
|Segments Covered||Drug Class, Type, Route of administration|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Companies Mentioned||United Therapeutics Corporation; Bayer; Gilead Sciences, Inc.; Johnson & Johnson; Viatris Inc.; GlaxoSmithKline; Sandoz Inc. (Novartis); Lupin Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals Inc|
By Drug Class Analysis
The prostacyclin and prostacyclin analogs segment dominated the market and accounted for the largest revenue share of around 47.0% in 2021.
The key factors contributing to the large share include a high demand and growing indications. In July 2021, Uptravi belonging to Prostacyclin and Prostacyclin Analogs segment received FDA approval for intravenous use in pulmonary arterial hypertension patients.
The SGC simulators segment is expected to grow at the fastest CAGR of over 5%. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling.
By Type Analysis
The branded segment dominated the market and accounted for the largest revenue share of 88.2% in 2021, while the generics segment is anticipated to witness the fastest CAGR of 5.9% in the coming years.
The factors contributing to the growth include the expiry of key patents, the rising launch of generics, growing consumption in developing markets, and initiatives by major companies.
Bayer on the other hand reported a significant increase in revenue of its branded PAH product- Adempas, driven by higher volume sales in the U.S. both in 2020 and 2021. However, the active ingredient patent of Adempas is set to expire in several key markets during the forecast period which may dampen sales in the coming years.
By Route of Administration Analysis
The oral segment dominated the market and held the largest revenue share of over 55.0% in 2021. This is attributable to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for the oral route of administration.
Letairis, Opsumit, Adcirca, and Revatio are some examples of oral PAH drugs. Johnson & Johnson’s Opsumit tablets, for instance, recorded total sales of USD 1.6 billion in 2020. The sales represented a 23.5% Y-o-Y growth compared to 2019.
The intravenous/ subcutaneous segment is anticipated to register the fastest growth of over 5.0% over the forecast period due to increasing indications and approvals by regulatory agencies and advances in drug delivery systems to increase patient compliance.
By Regional Analysis
North America dominated the pulmonary arterial hypertension market and held the largest revenue share of over 42.0% in 2021. The large share is due to the developed healthcare infrastructure in the U.S. and Canada that facilitates access to advanced therapeutics.
In the Asia Pacific, the market is estimated to witness the fastest CAGR of more than 6.0% over the next few years. This is owing to the growing consumption of generics, the presence of key pharmaceutical companies, and developing healthcare infrastructure.
United Therapeutics Corporation
Gilead Sciences, Inc.
Johnson & Johnson
Sandoz Inc. (Novartis)
Lupin Pharmaceuticals, Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
By Drug Class
Endothelin Receptor Antagonists (ERAs)
Prostacyclin and Prostacyclin Analogs
By Route of Administration
The pulmonary arterial hypertension market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of pulmonary arterial hypertension market for the base year 2021 and the forecast between 2022 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global pulmonary arterial hypertension market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the pulmonary arterial hypertension market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted pulmonary arterial hypertension market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the pulmonary arterial hypertension capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of pulmonary arterial hypertension by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global pulmonary arterial hypertension market. These figures have been provided in terms of both revenue and volume for the period 2019 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major pulmonary arterial hypertension market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of pulmonary arterial hypertension market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the pulmonary arterial hypertension industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
pulmonary arterial hypertension market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to pulmonary arterial hypertension market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of pulmonary arterial hypertension market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new pulmonary arterial hypertension market. These factors have benefited the growth of the global market for pulmonary arterial hypertension. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for pulmonary arterial hypertension. The global market is segmented on the basis of region, application, end-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of pulmonary arterial hypertension are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
The study objectives of this report are:
Cancer Supportive Care Drugs Market (By Therapeutic Class: G-CSFs, Anti-emetics, ESAs, Bisphosphonates, Opioids, NSAIDs & Others)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
eHealth Devices Market( By Type: Blood Pressure Meters, Fever Meters, Glucose Meters, Care Phone/Social Alarms)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Tracheostomy Products Market (By Demographics: Adults, Paediatrics/Neonatal; By Type: Tracheostomy Tubes, Ventilation Accessories ; By End Use: Hospitals & Surgery Centers, Ambulatory Care Centers, Home Care Settings, Others; By Technique) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Smart Blood Pressure Monitoring Devices Market (By Type: Upper Arm Blood Pressure Monitor, Wrist Blood Pressure Monitor Finger Blood Pressure Monitor; By Technology: Wi-Fi Based/4G, Bluetooth Based)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Laparoscopic Electrodes Market (By Application: Bariatric, General Surgeries; By Product: Monopolar, Bipolar Electrodes; By End User: Hospital, Ambulatory)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...